The agreement covers a suite of software tools and databases for functional data analysis MetaCore, which is used for biomarker discovery, target identification and validation.
MetaCore features a set of tools for parsing, visualization and analysis of metabolic data and generation of merged metabolic/signaling networks starting from compounds structures. Such capability is key for toxicity studies and medicinal chemistry.
"We have been working for Boehringer Ingelheim more than a year and we are very pleased with their decision to expand their licenses. This year, we have already seen a substantial increase in the number of MetaCore seats within Pharmaceutical accounts, which is partly due to maturing of functional analysis technology," said Julie Bryant, GeneGo's VP of Business Development.
"We also think that the end users, wet lab scientists, see biologically relevant results using MetaCore that they are not getting from other tools," Bryant added.